He Said, Biogen Said

Carl Icahn is no stranger to boardroom battles. On Monday, the longtime equity-shakeup artist fired off his third letter in as many weeks to Biogen Idec (Nasdaq: BIIB  ) investors, calling for an overhaul of its board of directors.

Whether with Yahoo! (Nasdaq: YHOO  ) or other companies like ImClone Systems (Nasdaq: IMCL  ) , Icahn hasn't waited long to rattle any boards of directors or management teams with whom he disagrees. In conjunction with Biogen's upcoming annual meeting and his own attempt to get his candidates voted onto Biogen's board, Icahn's letter reiterated his position that Biogen deliberately sabotaged its aborted sales process last year.

Icahn claimed that Biogen's current board of directors was asleep at the wheel while multiple drugmakers were considering placing a bid on Biogen last year. Because of Biogen's "missteps" and "poor design" of the bidding process, Icahn charged that all the potential bidders are now locked out "from talking to (Biogen) about an acquisition".

The way the bidding process shook out last year has always been Icahn's biggest complaint about Biogen's recent performance. He balked when rumors briefly swirled earlier in the year that Biogen might be looking to make a large acquisition of its own, but overall, he has made few complaints about Biogen's operational performance. With revenue up 18% and free cash flow up 15% last year, despite a tough operating environment for many drugmakers, Icahn would have trouble arguing that Biogen is failing operationally.

Perhaps tellingly, yesterday several independent shareholder-advisory firms sided against voting for Icahn's slate of board nominees. Even if Icahn succeeds at the company's annual meeting, adding a few more independent directors to Biogen's board won't give him control over Biogen by any means.

Biogen is an active Stock Advisor pick. See all the Gardner brothers' market-beating recommendations with a free 30-day trial subscription.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 662758, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:02:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,197.62 -1.71 -0.01%
S&P 500 2,136.43 -3.00 -0.14%
NASD 5,226.63 -23.64 -0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 2:46 PM
BIIB $291.81 Down -4.66 -1.57%
Biogen CAPS Rating: *****
IMCL $69.99 Down +0.00 +0.00%
ImClone Systems CAPS Rating: **
YHOO $41.98 Down -0.10 -0.24%
Yahoo CAPS Rating: **